Stocks Health care CYCN
NASDAQ · Health careCyclerion Therapeutics, Inc. (CYCN)
It posted a net loss of $6.7M. At June 30, 2026 it held $1.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
What Cyclerion Therapeutics, Inc. does
Cyclerion Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CYCN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.1M | -$3.5M | -$1.11 | n/a |
| 2024 | $2M | -$3.1M | -$1.21 | n/a |
| 2023 | $0 | -$5.3M | -$2.25 | n/a |
| 2022 | $297K | -$44.1M | -$20.28 | -$40.6M |
| 2021 | $3.9M | -$51.6M | -$26.50 | -$36.5M |
| 2020 | $2.3M | -$77.8M | -$51.40 | -$74M |
Where CYCN ranks in Health care
Latest SEC filings
What Cyclerion Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026Passive stake (5% or more) SCHEDULE 13G
- September 16, 2026Passive stake (5% or more) SCHEDULE 13G
- September 15, 2026Activist stake (5% or more) SCHEDULE 13D
- September 11, 2026Activist stake (5% or more) SCHEDULE 13D
- September 11, 2026
- August 27, 2026
- August 25, 2026Form 425 filing 425
- August 25, 2026Other event 8-K
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Cyclerion Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns CYCN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tomas Kiselak13D, may seek influence with 4 related filers | 19.99% | September 11, 2026 |
| Peter M. Hecht13D, may seek influence | 19.4% | July 20, 2026 |
| Fmr LLC13G, passive with 1 related filers | 15% | May 7, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13D, may seek influence with 8 related filers | 9.9% | September 15, 2026 |
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 7.33% | August 14, 2026 |
| ADAR1 Capital Management, LLC13G, passive with 1 related filers | 7% | August 14, 2026 |
| General Atlantic, L.P.13G, passive with 16 related filers | 6.8% | September 18, 2026 |
| Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.13G, passive | 6.1% | September 16, 2026 |
| J. Wood Capital Advisors LLC13G, passive with 1 related filers | 5.4% | October 17, 2025 |
Largest institutional holders
Insiders
Questions about CYCN
What does Cyclerion Therapeutics, Inc. do?
Cyclerion Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CYCN.
Is Cyclerion Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $6.7M.
When did Cyclerion Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from September 23, 2026.
Similar companies
Compare CYCN with
Follow CYCN
Get an email when Cyclerion Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CYCN: get an email when it filesWhere the numbers come from
Financial figures are the values Cyclerion Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.